Novartis may take a leaf out of its past deal-book as the Swiss drugmaker conducts a review into some of its underperforming businesses, a board member said.
New chairman Joerg Reinhardt has launched a review of the drugmaker’s portfolio fanning speculation that some of the company’s smaller units could be sold, spun-off or integrated into other divisions.
Help employers find you! Check out all the jobs and post your resume.
